Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630043 · ClinicalTrials.gov registry record · Phase 1
Trial of Tolcapone With Oxaliplatin for Neuroblastoma
A Phase 1 study, sponsored by Giselle Sholler.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02630043 is a Phase 1 study that was terminated before completion, run by Giselle Sholler. The registered enrollment target is 5 participants.
The verdict
NCT02630043, a Phase 1 study, was terminated before completion, sponsored by Giselle Sholler.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone and in combination with oxaliplatin, for relapsed and refractory neuroblastoma. Tolcapone is approved by the U.S. Food and Drug Administration (FDA) for adults, but is an investigational drug in this study because it has not been approved in pediatrics for this indication. Oxaliplatin, although a drug approved by the FDA for other cancers, is investigational for treatment of neuroblastoma in this study. This study will look at the safety and tolerability of tolcapone in combination with oxaliplatin as well as the tumors response to this study drug.
Interventions
- DRUG Oxaliplatin
- DRUG Tolcapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-12 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02630043
The ClinicalTrials.gov registry entry for NCT02630043 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT02630043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02630043 about?
NCT02630043 is a clinical study titled "Trial of Tolcapone With Oxaliplatin for Neuroblastoma". The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone and in combination with oxaliplatin, for relapsed and refractory neuroblastoma. Tolcapone is approved by the U.S. Food and Drug Administration (FDA) for adults, but is an investigational drug in this study be...
What is the current status of trial NCT02630043?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2015-12. Estimated completion is 2019-07.
What interventions are being tested in trial NCT02630043?
The interventions under investigation include: Oxaliplatin (DRUG), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT02630043?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.